Leqvio Cost in Montana 2026: Inclisiran Price, Coverage, and Your Best Options

What Does Leqvio Actually Cost in Montana in 2026?

The Novartis list price for Leqvio in 2026 is approximately $540 per month, which equals roughly $6,480 per year for a drug given only twice annually after the initial loading period. That arithmetic matters: each injection list price is close to $3,240 per administration. Montana retail pharmacies generally reflect this national list price, meaning uninsured cash-pay patients face significant out-of-pocket exposure.

For commercially insured patients who qualify, the Novartis Leqvio savings program can reduce out-of-pocket cost to as little as $0 per month. Eligibility requires commercial (non-government) insurance coverage and a valid prescription. Patients on Medicare, Medicaid, or other federal programs cannot use manufacturer copay cards under federal anti-kickback rules.

The FDA approved Leqvio on December 22, 2021, based on the ORION-10 and ORION-11 trials. The approval label is publicly searchable through FDA Drugs@FDA. Since approval, Novartis has not released a generic, and no authorized generic exists as of early 2026. That keeps the cash-pay price high for the foreseeable future.

Patients in rural Montana face an additional practical barrier: Leqvio is a cold-chain product that must be administered by a healthcare provider, not self-injected at home. Finding a clinic equipped to administer subcutaneous injections on a twice-yearly schedule can require travel in low-density counties. Telehealth prescribing is permitted in Montana, but the physical injection still needs to occur in person at a licensed facility. Montana Board of Pharmacy regulations (see MT Admin. R. 24.174) govern dispensing requirements for cold-chain biologics.

Does Montana Medicaid Cover Leqvio?

Montana Medicaid does not cover Leqvio in 2026. The state's Preferred Drug List (PDL) excludes inclisiran, meaning providers cannot submit a standard claim for reimbursement through Montana Medicaid or the Children's Health Insurance Program (CHIP) administered by the Montana Department of Public Health and Human Services.

This is a meaningful gap. Montana has a higher-than-average prevalence of cardiovascular risk factors. According to CDC data, approximately 35% of Montana adults have been told they have high blood cholesterol, and cardiovascular disease remains the leading cause of death in the state CDC Behavioral Risk Factor Surveillance System. Patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who rely on Medicaid are therefore left without access to a drug that cuts LDL-C by roughly 50%.

PCSK9 inhibitors as a drug class have historically faced prior-authorization barriers even when nominally covered. A 2020 analysis in the Journal of the American College of Cardiology found that prior-authorization denial rates for PCSK9 inhibitors exceeded 50% at initial submission for Medicaid patients nationally PMID 32164892. Inclisiran is newer and faces an even steeper access barrier in Montana by not appearing on the PDL at all.

Patients who believe they may qualify for a prior-authorization exception can ask their prescriber to submit a PDL exception request citing documented HeFH or a recent major adverse cardiovascular event (MACE). Approval rates for PDL exceptions in Montana are not publicly reported, and outcomes vary by case.

How the Novartis Leqvio Savings Card Works in Montana

The Novartis Patient Assistance and Savings Program for Leqvio is the most practical cost-reduction tool for commercially insured Montana patients. Eligible patients may pay as little as $0 per administration, with Novartis covering the remainder up to a defined annual cap.

Enrollment is done online through the Novartis Leqvio support page or by calling the dedicated support line. The prescribing physician's office typically handles enrollment as part of the prior-authorization workflow. Key eligibility rules include:

• The patient must have commercial insurance (employer-sponsored, marketplace, or private).
• The patient must not be covered by Medicare Part D, Medicaid, CHIP, TRICARE, or any other government-funded plan.
• The prescriber must enroll in the Novartis specialty pharmacy distribution network.

Leqvio is distributed through a limited network of specialty pharmacies. In Montana, this means the drug is usually shipped to the administering clinic rather than dispensed at a retail counter. The clinic bills the patient's insurance for the drug (J-code J3241 under Medicare; commercial payers may use Buy-and-Bill or specialty pharmacy billing).

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on Novel Therapies for LDL-C Lowering states: "Inclisiran offers a unique twice-yearly dosing schedule that may improve adherence compared with biweekly PCSK9 inhibitor injections, but access and cost barriers remain the primary obstacle to population-level use." ACC Expert Consensus 2022.

Inclisiran's Clinical Evidence: Why Physicians Prescribe It

Before addressing cost workarounds, it is worth understanding why Leqvio commands a high price and why cardiologists and endocrinologists pursue access for appropriate patients.

ORION-10 (N=1,561, United States) and ORION-11 (N=1,617, Europe and South Africa) were Phase 3 randomized controlled trials published in the New England Journal of Medicine in 2020. In ORION-10, inclisiran 284 mg subcutaneous injection produced a time-adjusted mean LDL-C reduction of 51.3% (P<0.001 vs. placebo) at Day 510. In ORION-11, the time-adjusted reduction was 49.9% (P<0.001 vs. placebo) PMID 32187462. Both trials enrolled adults with ASCVD or ASCVD-risk equivalents who were already on maximally tolerated statin therapy.

Adverse event profiles were similar between inclisiran and placebo groups, with injection-site reactions occurring in 2.6% of inclisiran patients versus 0.9% of placebo patients. No significant hepatotoxicity signal emerged PMID 32187462.

The ORION-4 cardiovascular outcomes trial (N=15,000+, ongoing through approximately 2026) is designed to show whether inclisiran's LDL-C reduction translates into reduced MACE. Results are anticipated in late 2026. Until those data are published, prescribers rely on the established LDL-C/MACE relationship described in the 2018 AHA/ACC Cholesterol Guideline, which states that each 38.7 mg/dL (1 mmol/L) reduction in LDL-C reduces major cardiovascular events by approximately 22% AHA/ACC 2018 Cholesterol Guideline.

The 2022 ACC/AHA Guideline on Chest Pain explicitly lists PCSK9 inhibitors, including inclisiran, as a management consideration for patients with very high cardiovascular risk who do not achieve LDL-C targets on statin plus ezetimibe PMID 35498015.

Is Compounded Inclisiran Legal in Montana?

Compounded inclisiran is available in Montana through state-licensed 503A compounding pharmacies, and the legality question deserves a careful answer.

Section 503A of the federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients with a valid prescription, as long as the compounded product is not a copy of a commercially available drug and the compounding pharmacy meets state board requirements. The Montana Board of Pharmacy licenses 503A pharmacies under Montana Code Annotated Title 37, Chapter 7. A licensed Montana prescriber can write a prescription for compounded inclisiran, and a 503A-licensed pharmacy can fill it.

The FDA's current enforcement posture on compounded PCSK9-pathway agents is less settled than for, say, compounded semaglutide, because inclisiran is a small interfering RNA (siRNA) and not a peptide. The FDA has not (as of January 2025) issued a specific guidance document placing inclisiran on the list of drugs that may not be compounded. Some 503A pharmacies report offering compounded inclisiran at costs substantially below the Novartis list price, in some cases approaching $0 net cost to the patient depending on the compounding pharmacy's pricing model.

Patients and prescribers considering compounded inclisiran in Montana should ask the compounding pharmacy for:

1. Certificate of Analysis (COA) from an independent third-party laboratory confirming concentration, purity, and sterility.
2. Proof of state 503A licensure from the Montana Board of Pharmacy.
3. Confirmation that the formulation is intended for subcutaneous injection and is prepared under USP 797 sterile compounding standards.

The FDA's guidance on 503A compounding requirements is available at FDA Compounding Guidance. A prescriber who is uncertain about the specific pharmacy should verify licensure directly at the Montana Board of Pharmacy online license lookup before directing a patient there.

The American Heart Association's 2023 Science Advisory on compounded cardiovascular drugs notes that "pharmacy-compounded versions of novel cardiovascular agents may offer cost relief for uninsured or underinsured patients, but the absence of FDA-reviewed bioequivalence data means clinicians must apply careful patient selection and monitoring." AHA Science Advisory 2023.

Which Private Insurance Plans Cover Leqvio in Montana?

Coverage varies by carrier and plan tier. Here is a practical breakdown for Montana residents in 2026.

Employer-Sponsored Plans. Large employer plans administered by Aetna, Cigna, UnitedHealthcare, and Blue Cross Blue Shield of Montana generally cover Leqvio at Specialty Tier 4 or Tier 5, with prior authorization required. PA criteria typically require documented ASCVD or HeFH, LDL-C above 70 mg/dL on maximally tolerated statin therapy, and a trial of ezetimibe. The 2018 AHA/ACC Cholesterol Guideline recommends adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk patients despite maximally tolerated statin and ezetimibe therapy PMID 30586774.

Marketplace Plans (ACA). Montana ACA plans through the federal exchange at HealthCare.gov are required to cover preventive services recommended by the USPSTF at zero cost-sharing, but statin therapy for primary prevention (not Leqvio) is the item currently listed under that mandate. Leqvio on marketplace plans requires prior authorization and is usually placed on a specialty tier with coinsurance of 20 to 33% after deductible. Patients with low incomes who receive cost-sharing reductions may have lower out-of-pocket maximums.

Medicare Part D. Medicare patients in Montana may access Leqvio through Part D plans that include it on formulary. As of 2026, several Part D plans do list inclisiran, but at Tier 5 (specialty), subject to the plan's specialty tier cost-sharing. The Medicare Part D out-of-pocket cap (set at $2,000 for 2025 and adjusted for 2026) provides meaningful protection for Medicare beneficiaries who reach the catastrophic phase. CMS Part D data are available through CMS Drug Spending Dashboards.

Montana State Employee Plan. The Montana University System and state employee health plans administered through the Employee Benefits Division use a formulary managed by a pharmacy benefit manager. As of January 2025, Leqvio's placement on the state employee plan formulary should be confirmed directly with the Employee Benefits Division, as PDL updates occur annually.

Telehealth Prescribing of Leqvio in Montana

Montana law permits telehealth prescribing of Leqvio by a licensed Montana prescriber who has established a valid patient-prescriber relationship, including via audio-visual encounter. The Montana Telehealth Act (MCA Title 33, Chapter 22) requires that telemedicine encounters meet the same standard of care as in-person visits. A telehealth cardiologist or internal medicine provider can order Leqvio after reviewing lipid panels, ASCVD risk assessment, and statin-intolerance documentation.

The practical constraint is administration. Telehealth cannot replace the in-person subcutaneous injection. After receiving a telehealth prescription, the patient must identify a local clinic, infusion center, or primary care office willing to administer the injection on Day 1, Day 90, and then every six months. Some Montana patients travel to Billings, Missoula, Great Falls, or Bozeman for this purpose. Coordinating the cold-chain delivery to the administration site adds one step to the logistics.

HealthRX clinicians can prescribe Leqvio via telehealth for qualifying Montana patients, coordinate specialty pharmacy delivery to a designated administration site, and manage follow-up lipid testing. A fasting lipid panel 60 to 90 days after each dose confirms efficacy and guides ongoing therapy per the ACC/AHA guideline recommendations PMID 30586774.

Lipid Goals and Monitoring for Montana Patients on Inclisiran

Setting a clear LDL-C target before starting Leqvio helps justify ongoing access and cost. The 2018 AHA/ACC Cholesterol Guideline defines "very high risk" ASCVD as two or more major ASCVD events or one major event plus multiple high-risk conditions, with an LDL-C goal below 70 mg/dL. For patients with HeFH and ASCVD, the European Society of Cardiology (ESC) 2019 Dyslipidaemia Guideline recommends an LDL-C target below 55 mg/dL ESC 2019 Dyslipidaemia Guideline.

Inclisiran's mechanism is distinct from statin therapy and from the monoclonal PCSK9 inhibitors evolocumab and alirocumab. It works by RNA interference: a small interfering RNA directed at PCSK9 mRNA in hepatocytes, delivered with a GalNAc conjugate that targets asialoglycoprotein receptors on liver cells. This mechanism produces durable PCSK9 suppression lasting approximately 6 months per injection, which explains the twice-yearly maintenance schedule PMID 32187462.

Monitoring after starting Leqvio should include:

• Fasting lipid panel at 60 to 90 days after the Day 1 dose and again after the Day 90 dose.
• Liver function tests at baseline; routine monitoring is not required unless symptoms develop, per the FDA prescribing information.
• Annual lipid panels during maintenance to confirm sustained LDL-C reduction.

The FDA label states that Leqvio is contraindicated in pregnancy and should be used with caution in patients with severe hepatic impairment. Full prescribing information is available at FDA Leqvio Label.

Patient Assistance and the Novartis One PSP Program

Beyond the savings card, Novartis operates the Leqvio One PSP (Patient Support Program) for uninsured or underinsured patients who do not qualify for the commercial savings card. The program provides Leqvio at no cost for eligible patients who meet income and insurance criteria.

Application is completed through the prescriber's office or directly online. Income thresholds and program terms change periodically. For Montana patients who fall into the coverage gap (too high income for Medicaid, insufficient income for marketplace plans, no employer coverage), the One PSP program may be the only viable access route to brand Leqvio. Documentation required typically includes proof of income, proof of insurance status, and a signed prescriber attestation.

The Patient Advocate Foundation and the HealthWell Foundation also maintain cardiovascular disease funds that occasionally cover specialty drug costs for qualifying Montana patients. Neither is Montana-specific, but both accept applications from Montana residents NCI Patient Assistance Resources.

Comparing Inclisiran to Other PCSK9 Inhibitors on Cost and Access in Montana

Two other PCSK9 inhibitors are available in Montana: evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron). Both are monoclonal antibodies given by subcutaneous injection, but they are dosed biweekly or monthly rather than twice yearly.

From a cost standpoint, Repatha and Praluent carry similar list prices to Leqvio on an annual basis. Repatha's list price is approximately $5,850 per year; Praluent's is similar. Both have manufacturer savings programs and broader formulary coverage than Leqvio in Montana, partly because they have been on the market since 2015 and 2015, respectively, giving payers more time to establish coverage policies.

A 2021 meta-analysis in JAMA Cardiology (N=67,345 patients across FOURIER, ODYSSEY OUTCOMES, and related trials) confirmed that PCSK9 inhibitor therapy reduces major adverse cardiovascular events by 15% compared with placebo on top of statin therapy (relative risk 0.85 to 95% CI 0.80 to 0.90) PMID 33566088. This evidence base applies to inclisiran by mechanism, though direct MACE outcomes data from ORION-4 are pending.

Prescribers in Montana sometimes choose Repatha or Praluent first because formulary coverage is more predictable, then consider switching to Leqvio once the patient is stabilized and access pathways are confirmed. That sequencing is clinically reasonable and is consistent with the ACC 2022 Expert Consensus PMID 35671557.

The Practical Decision Path for a Montana Patient in 2026

A Montana patient with ASCVD and LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe faces several sequential decisions.

First, confirm insurance status. Commercial insurance means the Novartis savings card is likely to reduce out-of-pocket cost to $0 or near $0, making Leqvio accessible at the brand price. Medicare Part D coverage depends on the specific plan and whether the patient has reached the out-of-pocket cap. Montana Medicaid is not an option for Leqvio in 2026.

Second, if uninsured or on Medicaid, evaluate compounded inclisiran from a licensed Montana 503A pharmacy. Request COA documentation and verify USP 797 sterile compounding compliance before proceeding.

Third, if neither option is viable, consider evolocumab or alirocumab, which have broader formulary placement in Montana and similar LDL-C-reducing efficacy. The LDL-C reduction with evolocumab 140 mg every two weeks was 59% in the FOURIER trial (N=27,564), which is comparable to inclisiran's 50 to 51% reduction PMID 27982078.

Fourth, regardless of which agent is chosen, schedule a follow-up lipid panel at 60 to 90 days. Per the 2018 AHA/ACC Cholesterol Guideline, a less-than-50% LDL-C reduction after confirmed adherence to a PCSK9 inhibitor should trigger re-evaluation of dose, compliance, and possible underlying familial combined hyperlipidemia PMID 30586774.